MarketCatalyst
← Back to Resources
Earnings

Nu Q3 2026 Revenue Tops Estimates at $6.30B, but EPS Misses at $0.22

Revenue of $6.30B vs. $5.96B expected and adjusted EPS of $0.22 vs. $0.23; revenue up 57% from a year earlier.

Published Nov 12, 2026 · 6:01 PM ET · 2 min read

Nu (NU) posted mixed third-quarter 2026 results, with revenue above the estimate and adjusted EPS below it. Revenue was $6.30 billion, up 57% from a year earlier, above the $5.96 billion estimate, and adjusted EPS was $0.22, up 29% from a year earlier, below the $0.23 estimate.

Shares rose 4.0% in after-hours trading as of 6:01 p.m. ET, to $12.30 from a $11.83 close.

$0.22
Adjusted EPS, up 29% YoY vs. $0.23 estimate
$6.30B
Revenue, up 57% YoY vs. $5.96B estimate
+4.0%
Shares after hours as of 6:01 p.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS$0.23$0.22Miss by 2.8%
Revenue$5.96B$6.30BBeat by 5.7%
ChangeYoYQoQ
Adjusted EPS▲ 29%Unchanged
Revenue▲ 57%▲ 7.2%

By our calculation, revenue was $337.7 million above the estimate and adjusted EPS was $0.01 below it. The QoQ column compares with the previous quarter's revenue of $5.88 billion and adjusted EPS of $0.22. The YoY column compares with $4.00 billion and $0.17 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 8 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $4.00 billion, $4.90 billion, $5.32 billion, $5.88 billion and $6.30 billion.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of $0.25 and revenue of $6.30 billion next quarter, based on 6 analysts.
  • Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 57% increase to $6.30 billion.
  • Estimate record. Whether Nu returns to beating EPS estimates, which it did in 3 of its last 8 reports.
  • Related coverage. See our reports on Tamboran Resources, Forgent Power Solutions, AnaptysBio and Arrowhead Pharmaceuticals.

Sources: Results are from Nu's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Nu's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.